XY Capital Ltd Buys Shares of 33,970 Sanofi $SNY

XY Capital Ltd purchased a new stake in shares of Sanofi (NASDAQ:SNY) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 33,970 shares of the company’s stock, valued at approximately $1,603,000. Sanofi accounts for 0.8% of XY Capital Ltd’s holdings, making the stock its 26th largest position.

Other large investors also recently modified their holdings of the company. Waterfront Wealth Inc. increased its holdings in Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after acquiring an additional 214 shares during the period. HighPoint Advisor Group LLC grew its position in shares of Sanofi by 2.3% during the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after purchasing an additional 226 shares in the last quarter. HM Payson & Co. increased its holdings in shares of Sanofi by 3.4% in the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after purchasing an additional 235 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. raised its position in shares of Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after buying an additional 238 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its position in shares of Sanofi by 2.8% in the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after buying an additional 241 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SNY shares. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Citigroup began coverage on Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Finally, Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Trading Down 0.1%

Shares of SNY stock opened at $43.60 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $46.85 and a two-hundred day moving average price of $48.24. Sanofi has a 12-month low of $43.34 and a 12-month high of $59.17. The firm has a market cap of $106.34 billion, a P/E ratio of 12.11, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.